HemaSphere (May 2023)
P53 REAL-WORLD TREATMENT SEQUENCES AND COSTS OF 96 PATIENTS WITH MULTIPLE MYELOMA FROM DIAGNOSIS TO DEATH
- M.R. Seefat,
- D.G.J. Cucchi,
- K. Groen,
- M.L. Donker,
- K.G. van der Hem,
- M. Westerman,
- A.M. Gerrits,
- A. Beeker,
- N. van de Donk,
- H.M. Blommestein,
- S. Zweegman
Affiliations
- M.R. Seefat
- 1 Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
- D.G.J. Cucchi
- 1 Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
- K. Groen
- 1 Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
- M.L. Donker
- 1 Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
- K.G. van der Hem
- 3 Department of Internal Medicine, Zaans Medical Center, Zaandam, the Netherlands
- M. Westerman
- 4 Department of Internal Medicine, Northwest Clinics, Alkmaar, the Netherlands
- A.M. Gerrits
- 5 Department of Internal Medicine, OLVG, Amsterdam, the Netherlands
- A. Beeker
- 6 Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, the Netherlands
- N. van de Donk
- 1 Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
- H.M. Blommestein
- 7 Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands
- S. Zweegman
- 1 Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
- DOI
- https://doi.org/10.1097/01.HS9.0000936340.30450.37
- Journal volume & issue
-
Vol. 7,
no. S2
pp. 39 – 40
Abstract
No abstracts available.